ADHD 2023 - Congress Programme

37 SCIENTIFIC PROGRAMME Saturday, 20 May 2023 P-23-002 Phase IV, pragmatic, open-label, real world evidence study of methylpheni- date hydrochloride controlled-release capsules (PRC-063) and lisdexamfetamine dimesylate for treatment of pediatric and adult ADHD J. Ratz, Canada G. Parhar, A. Parhar, V. Tourjman, S. Khattak, T. Ahmed, G. Donnelly P-23-003 Psychostimulants and Raynaud's phe- nomenon in young population I. Durán Cristóbal, Spain A. Noguero-Alegre P-23-004 Factors associated with treatment re- sponse to atomoxetine and methylphe- nidate in Asian children with ADHD T. Lee, Republic of Korea K. Park, S. Shon, H. Kim P-23-005 Modelling ADHD treatment outcomes in an Australian child and youth mental health service: Which factors are most important? C. Middeldorp, The Netherlands L. Payne, K. Stephens, J. Tiego, J. Scott, M. Bellgrove, D. Coghill, E. Sciberras P-23-006 Offshoots of the titration process of the multimodal treatment of ADHD study: A qualitative inquiry into the reasons for failure/success in clinical uptake P. Robaey, Canada E. Carreiro P-23-007 Deciding on the best dose in stimulant titration for ADHD treatment: Agreement between a shared decision process with parents, expert decision and an instant- runoff voting algorithm P. Robaey, Canada E. Carreiro, S. Alharti, A. Boafo, F. O’Kelly, N. Barrowman, V. Bijelic P-23-008 Shared decision making stimulant titra- tion for ADHD in the children's hospital of Eastern Ontario: A quantitative and qualitative investigation P. Robaey, Canada E. Fletcher, A. Samson P-23-009 Genetic and lifestyle risk factors for psy- chopathology in early adolescence Y. Shi, The Netherlands B. Franke, E. Sprooten, N. Roth Mota P-23-010 Effects of stimulant medication on symp- tom interrelations in ADHD Z. Van Der Pal, The Netherlands A. van Keeken, A. Bruijn, H. Geurts, D. Borsboom, L. Douw, M. NeuroIMAGE project, L. Reneman, T. Blanken, A. Schrantee P-23-011 Elucidating the functional effects of Omega-3 fatty acids as a treatment in ADHD N. Walter, Switzerland C. Yde Ohki, S. Ruhstaller, S. Walitza, E. Grünblatt P-23-012 A multicenter, randomized, double-blind, placebo-controlled phase III study to eval- uate the efficacy and safety of EDP125 in children and adolescent patients with ADHD Q. Xu, China Z. Lin, Y. Yang, Y. Zhong, X. Wang, B. Yao, W. Wang P-23-013 A meta-analysis on efficacy and safety of jingling oral liquid combined with methylphenidate hydrochloride in the treatment of ADHD W. Yu, China P-24 Guided Poster Tour 14:00–15:30 Onyx Lounge Quality of life/Caregiver burden I Chair: M. Bellgrove, Australia P-24-002 Resilience and vulnerability as media- tors of school achievement in adolescents with ADHD: A population-based study R. Arruda, Brazil P. Custódio D’Amico, L. Marques, L. Anunciação, M. Arruda P-24-003 The mediating role of executive function- ing on school achievement in children with ADHD: A population-based study R. Arruda, Brazil P. Custódio D’Amico, L. Marques, L. Anunciação, M. Arruda P-24-004 Self-regulation is a family affair: The in- tergenerational relationship of executive functions and delay aversion amid the COVID‑19 pandemic J. Kneidinger, Germany J. García Alanis, R. Steinmayr, S. Schneider, H. Christiansen P-24-007 Navigating the academic journey: Unco- vering risk and protective factors for col- lege students with ADHD symptoms V. Müller, Hungary B. Pikó